Selexis & Teneobio have signed CLAs for the development of Teneobio’s UniAbs™, a new class of multi-specific biologics, for the treatment of multiple myeloma, lymphoma and prostate cancer
Selexis to Develop High-performance Research Cell Banks to Expedite the Manufacturing of Immunotherapy Clinical Candidates Designed to Target Cancers of High Unmet Need
Receive JSR Life Sciences news on your RSS reader.